What exactly did Raymond James do on March 16, 2026 for COGT analyst rating?

Raymond James reiterated a **Strong Buy** on **March 16, 2026**. The note kept the prior rating in place and did not publish a new price target in the StreetInsider summary.

How should investors interpret the COGT analyst rating maintained as Strong Buy?

A maintained Strong Buy signals continued analyst confidence. It supports a positive outlook but is not proof of future gains. Check fundamentals, trial timelines, and cash position alongside the COGT analyst rating.

Did the Raymond James note change the COGT price target?

The published summary on **March 16, 2026** did not include a new COGT price target. Investors should consult full reports or aggregated analyst tables for target updates.

What is Meyka AI's view after the COGT analyst rating reiteration?

Meyka AI rates COGT **B+**. That grade reflects benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus, and should be one input among many.

Analyst Ratings

Raymond James Maintains Strong Buy for Cogent Biosciences (COGT) March 2026

ByHuzaifa Zahoor March 17, 2026March 17, 2026

Raymond James maintained a Strong Buy on Cogent Biosciences, Inc. (COGT) on March 16, 2026. The COGT analyst rating stayed unchanged, signaling continued confidence from a major firm. Raymond James’ note produced a modest intraday move of 0.17% ($0.06). This reiteration matters because it keeps a high-profile broker supportive of Cogent amid a $5,791,178,698 market cap. Investors should weigh that affirmation alongside secondary metrics and broader biotech trends.